ESH MDS 2024 | Understanding the role of inflammation and the immunome in MDS pathophysiology
Shahram Kordasti, MSc, MD, PhD, King’s College London, London, UK, summarizes his talk on the role of the immunome in myelodysplastic syndromes (MDS). The multi-dimensional role of inflammation in the pathophysiology of the disease was discussed, including current knowledge of how inflammatory pathways, such as the NLRP3 pathway, contribute to genomic instability and disease progression. Dr Kordasti highlights that several approaches exist to control inflammation; however, there is limited understanding of how inflammation impacts the overall immune response, clinical presentation, and disease progression in MDS. This interview took place at the European School of Hematology 9th Translational Research Conference on Myelodysplastic Syndromes (ESH MDS) in Budapest, Hungary.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
I am going to talk about the immunome as a part of the general pathophysiology of MDS and what happens in terms of cellular immune response in MDS. In recent years, we know much better, in terms of inflammation, how the inflammatory pathway and NLRP3 pathway and the inflammation related to the myeloid cells which are mutated in these patients. We have a better insight about this inflammatory response and how it contributes to genomic instability, disease progression, and also there are plenty, well, several different approaches available to control inflammation...
I am going to talk about the immunome as a part of the general pathophysiology of MDS and what happens in terms of cellular immune response in MDS. In recent years, we know much better, in terms of inflammation, how the inflammatory pathway and NLRP3 pathway and the inflammation related to the myeloid cells which are mutated in these patients. We have a better insight about this inflammatory response and how it contributes to genomic instability, disease progression, and also there are plenty, well, several different approaches available to control inflammation. Of course, we can argue or discuss this further, whether Inhibiting inflammation is always a good thing or not. But generally speaking, there are tools available to control inflammation. But the aspect that we know exists, but our knowledge is far more limited, if you like, is the effect of this inflammation on the overall immune response, the composition of the cellular immune response, and how it may affect the clinical features, the disease progression, the outcome of the disease, response to different treatments- and these are the aspects which are not clear. So my talk will focus mainly on how inflammation and cellular immune response interact, with the example of our recent work that has just been published, and I’m going to discuss those, and how we can use these kind of findings to better stratify patients for better treatment.
Read more...
